Documents
Application Sponsors
| NDA 215014 | APELLIS PHARMACEUTICALS INC |  | 
Marketing Status
Application Products
| 001 | INJECTABLE;INJECTION | 1080MG/20ML(54MG/ML) | 0 | EMPAVELI | PEGCETACOPLAN | 
FDA Submissions
| TYPE 1; Type 1 - New Molecular Entity | ORIG | 1 | AP | 2021-05-14 | PRIORITY  | 
Submissions Property Types
CDER Filings
APELLIS PHARMACEUTICALS INC
cder:Array
(
    [0] => Array
        (
            [ApplNo] => 215014
            [companyName] => APELLIS PHARMACEUTICALS INC
            [docInserts] => ["",""]
            [products] => [{"drugName":"EMPAVELI","activeIngredients":"PEGCETACOPLAN","strength":"1080MG\/20ML(54MG\/ML)","dosageForm":"INJECTABLE;INJECTION","marketingStatus":"Prescription","te":"None","rld":"No","rs":"No"}]
            [labels] => [{"actionDate":"05\/14\/2021","submission":"ORIG-1","supplementCategories":"Approval","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2021\\\/215014s000lbl.pdf\"}]","notes":""}]
            [originalApprovals] => [{"actionDate":"05\/14\/2021","submission":"ORIG-1","actionType":"Approval","submissionClassification":"Type 1 - New Molecular Entity","reviewPriority":"PRIORITY; Orphan","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2021\\\/215014s000lbl.pdf\"},{\"name\":\"Letter (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/appletter\\\/2021\\\/215014Orig1s000ltr.pdf\"}]","notes":">"}]
            [supplements] => 
            [actionDate] => 2021-05-14
        )
)